Last reviewed · How we verify
HPV-16/18 vaccine
This vaccine stimulates the immune system to produce antibodies and cellular immunity against human papillomavirus types 16 and 18, preventing infection and associated cancers.
This vaccine stimulates the immune system to produce antibodies and cellular immunity against human papillomavirus types 16 and 18, preventing infection and associated cancers. Used for Prevention of cervical cancer caused by HPV-16 and HPV-18, Prevention of other HPV-16/18-associated cancers (anal, oropharyngeal, vulvar, vaginal).
At a glance
| Generic name | HPV-16/18 vaccine |
|---|---|
| Sponsor | Shanghai Zerun Biotechnology Co.,Ltd |
| Drug class | Prophylactic vaccine |
| Target | HPV-16 and HPV-18 L1 capsid proteins |
| Modality | Biologic |
| Therapeutic area | Oncology / Immunology |
| Phase | Phase 3 |
Mechanism of action
The HPV-16/18 vaccine is a prophylactic immunization that trains the body's adaptive immune response to recognize and neutralize HPV-16 and HPV-18 viral particles before infection occurs. By generating both humoral (antibody) and cell-mediated immune responses, the vaccine prevents persistent infection with these high-risk HPV types, which are responsible for the majority of cervical cancers and other HPV-associated malignancies.
Approved indications
- Prevention of cervical cancer caused by HPV-16 and HPV-18
- Prevention of other HPV-16/18-associated cancers (anal, oropharyngeal, vulvar, vaginal)
Common side effects
- Injection site pain or erythema
- Headache
- Myalgia
- Fever
- Fatigue
Key clinical trials
- Testing RG1-VLP Vaccine to Prevent HPV-related Cancers (PHASE1)
- Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (PHASE4)
- Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+ (PHASE2)
- A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV) (PHASE4)
- Study Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPV (PHASE2)
- Extended Follow-up of Women Who Received One, Two, and Three Doses of the HPV Vaccine in the Costa Rica Vaccine Trial (CVT), ESCUDDO-CVT Study
- A Cervical Cancer Prevention Program in Kenya (NA)
- The Mother-Daughter Project: Merck-4 (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HPV-16/18 vaccine CI brief — competitive landscape report
- HPV-16/18 vaccine updates RSS · CI watch RSS
- Shanghai Zerun Biotechnology Co.,Ltd portfolio CI